149 related articles for article (PubMed ID: 38063405)
1. Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study.
Tan S; Zhang S; Zhou N; Cai X; Yi C; Gou H
Cancer Med; 2023 Dec; 12(24):22038-22046. PubMed ID: 38063405
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
[TBL] [Abstract][Full Text] [Related]
3. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
Guo Y; Zhang W; Ying J; Zhang Y; Pan Y; Qiu W; Fan Q; Xu Q; Ma Y; Wang G; Guo J; Su W; Fan S; Tan P; Wang Y; Luo Y; Zhou H; Li J
Eur J Cancer; 2023 Mar; 181():26-37. PubMed ID: 36628898
[TBL] [Abstract][Full Text] [Related]
4. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A; Lonardi S; Garcia-Carbonero R; Elez E; Yoshino T; Sobrero A; Yao J; García-Alfonso P; Kocsis J; Cubillo Gracian A; Sartore-Bianchi A; Satoh T; Randrian V; Tomasek J; Chong G; Paulson AS; Masuishi T; Jones J; Csőszi T; Cremolini C; Ghiringhelli F; Shergill A; Hochster HS; Krauss J; Bassam A; Ducreux M; Elme A; Faugeras L; Kasper S; Van Cutsem E; Arnold D; Nanda S; Yang Z; Schelman WR; Kania M; Tabernero J; Eng C;
Lancet; 2023 Jul; 402(10395):41-53. PubMed ID: 37331369
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study).
Ishiyama S; Yamada T; Nakamura M; Enomoto M; Sugimoto K; Yokomizo H; Kosugi C; Ohta R; Ishimaru K; Sonoda H; Ishibashi K; Kuramochi H; Yoshida Y; Ichikawa D; Hirata K; Yoshida H; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
Int J Clin Oncol; 2022 Aug; 27(8):1300-1308. PubMed ID: 35635652
[TBL] [Abstract][Full Text] [Related]
6. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
[TBL] [Abstract][Full Text] [Related]
7. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.
Li J; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Xu R; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Shen L; Chen H; Wang S; Wang H; Fan S; Guo X; Wang N; Han R; Zhang B; Qin S
Adv Ther; 2020 Nov; 37(11):4585-4598. PubMed ID: 32901330
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Chen J; Wang J; Lin H; Peng Y
Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
[TBL] [Abstract][Full Text] [Related]
12. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).
Zhao W; Lei J; Ke S; Chen Y; Xiao J; Tang Z; Wang L; Ren Y; Alnaggar M; Qiu H; Shi W; Yin L; Chen Y
EClinicalMedicine; 2023 Dec; 66():102315. PubMed ID: 38024475
[TBL] [Abstract][Full Text] [Related]
13. The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer.
Song Y; Qu T; Zhang H; Sun Y; Cui C; Chi Y; Zhang W; Wang X; Yang L
Cancer Manag Res; 2021; 13():6199-6205. PubMed ID: 34393513
[TBL] [Abstract][Full Text] [Related]
14. Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer.
Liu S; Lu L; Pan F; Yang C; Liang J; Liu J; Wang J; Shen R; Xin FZ; Zhang N
Oncol Res; 2022 May; 29(1):25-31. PubMed ID: 35063062
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
17. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
Lu S; Chen G; Sun Y; Sun S; Chang J; Yao Y; Chen Z; Ye F; Lu J; Shi J; He J; Liu X; Zhang Y; Liu Z; Fang J; Cheng Y; Hu C; Mao W; Hu Y; Gong Y; Shan L; Yang Z; Song Y; Li W; Bai C; Wang B; Ma R; Zheng Z; Liu M; Jie Z; Cao L; Liao W; Pan H; Huang D; Chen Y; Yang J; Qin S; Ma S; Liang L; Liu Z; Zhou J; Tao M; Huang Y; Qiu F; Huang Y; Guan S; Peng M; Su W
Lung Cancer; 2020 Aug; 146():252-262. PubMed ID: 32592986
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI
BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study.
Zhang W; Han X; Yang L; Song Y; Xie L; Gai W; Wang Y; Shi Y
BMC Cancer; 2022 Oct; 22(1):1104. PubMed ID: 36307775
[TBL] [Abstract][Full Text] [Related]
20. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
Front Oncol; 2020; 10():587692. PubMed ID: 33282739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
